The present invention relates to a method of treating acute lymphoblastic leukemia in a patient in need thereof comprising administering to the […]

Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic […]

Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in […]

The present invention relates to lipid nanoparticle loaded with antitumoral agent andfunctionnalized to target immosuppressive cells. Inventors […]

The present invention relates to a method of treating acute lymphoblastic leukemia in a patient in need thereof comprising administering to the […]

Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have […]

The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells […]

Deciphering the impact of metabolic intervention on response to anticancer therapy represents a path toward improved clinical responses. Here, the […]

Adult T-cell leukemia/lymphoma (ATL) is an aggressive proliferation of mature activated CD4+ T cells associated with the human T-cell lymphotropic […]

The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present […]